VIKING THERAPEUTICS, INC. (VKTX) Return on equity 2016–2025
VIKING THERAPEUTICS, INC. (VKTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-56.3%FY2025 · since FY2016: -183.2% → -56.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -56.3% | -43.8 pp |
| FY2024 | -12.5% | +12.2 pp |
| FY2023 | -24.7% | +22.7 pp |
| FY2022 | -47.4% | -20.2 pp |
| FY2021 | -27.2% | -11.1 pp |
| FY2020 | -16.2% | -6.9 pp |
| FY2019 | -9.3% | -1.9 pp |
| FY2018 | -7.4% | +145.4 pp |
| FY2017 | -152.8% | +30.3 pp |
| FY2016 | -183.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More VKTX financial trends
VKTX RevenueVKTX Net incomeVKTX Net marginVKTX Gross profitVKTX Gross marginVKTX Operating incomeVKTX Operating marginVKTX Operating cash flowVKTX Free cash flowVKTX Capital expendituresVKTX Stock buybacksVKTX Dividends paidVKTX Total assetsVKTX Total liabilitiesVKTX Shareholders’ equityVKTX overview →